BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder

Depressive Disorder ◽

Allosteric Modulator ◽

Potential Utility ◽

Major Depressive ◽

Population Pharmacokinetic and Exposure-dizziness Modeling for a Metabotropic Glutamate Receptor Subtype 5 Negative Allosteric Modulator in Major Depressive Disorder Patients

Clinical and Translational Science ◽

10.1111/cts.12566 ◽

2018 ◽

Vol 11 (5) ◽

pp. 523-531

Author(s):

Valérie Cosson ◽

Franziska Schaedeli-Stark ◽

Mona Arab-Alameddine ◽

Clarisse Chavanne ◽

Elena Guerini ◽

...

Keyword(s):

Depressive Disorder ◽

Glutamate Receptor ◽

Metabotropic Glutamate Receptor ◽

Population Pharmacokinetic ◽

Receptor Subtype ◽

Allosteric Modulator ◽

Major Depressive ◽

Metabotropic Glutamate ◽

Preclinical Characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate N-Methyl-d-Aspartate 2B Receptor Negative Allosteric Modulator with Potential in Major Depressive Disorder

Journal of Pharmacology and Experimental Therapeutics ◽

10.1124/jpet.117.242784 ◽

2017 ◽

Vol 363 (3) ◽

pp. 377-393 ◽

Cited By ~ 5

Author(s):

Linda J. Bristow ◽

Jyoti Gulia ◽

Michael R. Weed ◽

Bettadapura N. Srikumar ◽

Yu-Wen Li ◽

...

Keyword(s):

Depressive Disorder ◽

Allosteric Modulator ◽

Major Depressive ◽

Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5

Expert Opinion on Investigational Drugs ◽

10.1517/13543784.2015.1074175 ◽

2015 ◽

Vol 24 (9) ◽

pp. 1247-1260 ◽

Cited By ~ 25

Author(s):

Kjell Fuxe ◽

Dasiel O Borroto-Escuela

Keyword(s):

Depressive Disorder ◽

Glutamate Receptor ◽

Metabotropic Glutamate Receptor ◽

Allosteric Modulator ◽

Major Depressive ◽

Metabotropic Glutamate Receptor 5 ◽

Metabotropic Glutamate ◽

Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder

The Journal of Clinical Psychiatry ◽

10.4088/jcp.18m12470 ◽

2020 ◽

Vol 81 (4) ◽

Cited By ~ 2

Author(s):

Daniel Umbricht ◽

Markus Niggli ◽

Patricia Sanwald-Ducray ◽

Dennis Deptula ◽

Rema Moore ◽

...

Keyword(s):

Depressive Disorder ◽

Controlled Trial ◽

Allosteric Modulator ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo ◽

Zuranolone—An Investigational Oral Neuroactive Steroid and Positive Allosteric Modulator of GABA Type A Receptors for Postpartum Depression and Major Depressive Disorder

US Neurology ◽

10.17925/usn.2020.16.2.81 ◽

2020 ◽

Vol 16 (2) ◽

pp. 81

Author(s):

Handan Gunduz-Bruce ◽

Keyword(s):

Postpartum Depression ◽

Depressive Disorder ◽

Type A ◽

Allosteric Modulator ◽

Neuroactive Steroid ◽

Major Depressive

Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial

Journal of Psychopharmacology ◽

10.1177/0269881112458728 ◽

2012 ◽

Vol 26 (12) ◽

pp. 1525-1539 ◽

Cited By ~ 38

Author(s):

Kari R Nations ◽

Peter Dogterom ◽

Roberta Bursi ◽

Jacques Schipper ◽

Scott Greenwald ◽

...

Keyword(s):

Depressive Disorder ◽

Ampa Receptor ◽

Controlled Trial ◽

Allosteric Modulator ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo

PMH76 - PATIENT REPORTED MEASURES OF DEPRESSIVE SYMPTOMS AND FATIGUE IN A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF THE GABAA RECEPTOR POSITIVE ALLOSTERIC MODULATOR SAGE-217 IN MAJOR DEPRESSIVE DISORDER

Value in Health ◽

10.1016/j.jval.2018.09.2887 ◽

2018 ◽

Vol 21 ◽

pp. S287

Author(s):

V. Bonthapally ◽

E. Suthoff ◽

P. Hodgkins ◽

H. Gunduz-Bruce ◽

R. Lasser ◽

...

Keyword(s):

Depressive Symptoms ◽

Depressive Disorder ◽

Controlled Trial ◽

Allosteric Modulator ◽

Phase 2 ◽

Major Depressive ◽

Patient Reported ◽

Patient Reported Measures

Potential utility of aripiprazole monotherapy for the treatment of major depressive disorder comorbid with obsessive-compulsive disorder

Psychiatry and Clinical Neurosciences ◽

10.1111/j.1440-1819.2009.01990.x ◽

2009 ◽

Vol 63 (4) ◽

pp. 593-593 ◽

Cited By ~ 2

Keyword(s):

Depressive Disorder ◽

Obsessive Compulsive Disorder ◽

Potential Utility ◽

Obsessive Compulsive ◽

Major Depressive ◽

Compulsive Disorder

O46. SAGE-217 a First in Class GABAA Receptor Positive Allosteric Modulator in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Phase 2 Placebo-Controlled Trial

Biological Psychiatry ◽

10.1016/j.biopsych.2018.02.333 ◽

2018 ◽

Vol 83 (9) ◽

pp. S127-S128

Author(s):

Handan Gunduz-Bruce ◽

Christopher Silber ◽

Anthony Rothschild ◽

Robert Riesenberg ◽

Abdul Sankoh ◽

...

Keyword(s):

Depressive Disorder ◽

Gabaa Receptor ◽

Controlled Trial ◽

Allosteric Modulator ◽

Phase 2 ◽

Major Depressive ◽

Double Blind

Zuranolone. GABA-A receptor positive allosteric modulator, Treatment of major depressive disorder, Treatment of postpartum depression

Drugs of the Future ◽

10.1358/dof.2019.44.6.2958473 ◽

2019 ◽

Vol 44 (6) ◽

pp. 443

Author(s):

R. Mehta ◽

R. Bhandari ◽

A. Kuhad ◽

A. Kuhad

Keyword(s):

Postpartum Depression ◽

Depressive Disorder ◽

Allosteric Modulator ◽

Major Depressive ◽

Gaba A ◽

Disorder Treatment